This work was supported by the National Natural Science Foundation of China(Grant No.:81774308);the Multi-center Clinical Research Project for Major Diseases of Shanghai Shenkang Hospital Development Center,China(Grant No.:SHDC2020CR1050B);the High-level University Building Innovation Team,China(Grant No.:601521D).
Trastuzumab has improved survival rates in human epidermal growth factor receptor 2(HER2)-positive breast cancer(BC),but drug resistance leads to treatment failure.Natural killer(NK)cell-mediated antibody-dependent ce...
目的 探讨MYB、Notch1免疫组化染色在经典型乳腺腺样囊性癌(classic adenoid cystic carcinoma of the breast, C-AdCC)、具有基底细胞样特征的实体型乳腺腺样囊性癌(solid-basaloid adenoid cystic carcinoma of the breast, SB-AdCC)...
the National Key Research and Development Program of China(2021YFC2300101).
The matrix protein 2 (M2) is a preferred target for developing a universal vaccine against the influenza A virus (IAV). This study aimed to develop a method for assessing antibody-dependent cell-mediated cytotoxicity ...
funded by the National Key R&D Program of China(2023YFE0116000);the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission(2022-2-018);Beijing Key Laboratory for HIV/AIDS Research(BZ0089);ANRS(Agence Nationale de Recherches sur le SIDA et les hépatites virales),the Investissements d’Avenir program managed by the ANR under reference ANR-10-LABX-77 and EHVA(N°681032,Horizon 2020);supported by the Strasbourg’s Interdisciplinary Thematic Institute(ITI)for Precision Medicine,TRANSPLANTEX NG,as part of the ITI 2021-2028 program of the University of Strasbourg,CNRS and INSERM;funded by IdEx Unistra[ANR-10-IDEX-0002]and SFRI-STRAT’US[ANR-20-SFRI-0012];the European regional development fund(European Union)INTERREG V program(project Personalis);MSD-Avenir grant AUTOGEN,for their financial supports.
The purpose of vaccination is to generate Neutralizing antibodies(NAbs),as these antibodies have neutralizing activity against viral infections such as HIV and SARS-CoV-2.NAb has high antiviral potency and therefore b...
supported by the National Natural Science Foundation of China(81872785);Shanghai Municipal Commission of Science and Technology of China(21S11904500);Major Scientific and Technological Special Project of Zhongshan City(191022172638719 and 210205143867019);CAS Bohai Rim Advanced Research Institute for Drug Discovery Project(LX211005);the Research&Development Plan in Key Areas of Guangdong Province(2022B1111070007).
Clinical application of PD-1 and PD-L1 monoclonal antibodies (mAbs) is hindered by their relatively low response rates and the occurrence of drug resistance. Co-expression of B7-H3 with PD-L1 has been found in various...